SCHEMBL5129089

SCHEMBL5129089

CC1CN(C(=O)C=Cc2ccc(C(F)(F)F)nc2N2CCCCC2)CCC12CC(c1ccccc1)=NO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 7/20 0.42
ATM Q13315 1/20 0.35
FAAH O00519 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
NPSR1 Q6W5P4 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
HPGD P15428 2/20 0.32
ADRB2 P07550 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ENPP2 Q13822 4/20 0.31
LMNA P02545 2/20 0.31
MAPT P10636 2/20 0.31
HTT P42858 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012871 1.00 TRPV1 (0.42) TRPV1ATMFAAHSCN10AMEN1
SCHEMBL5014538 0.86 TRPV1 (0.45) TRPV1ATMSCN10AMEN1KMT2A
SCHEMBL5130718 0.86 TRPV1 (0.45) TRPV1ATMSCN10AMEN1KMT2A
SCHEMBL5117701 0.79 TRPV1 (0.45) TRPV1ATMSCN10ACYP2C9ALDH1A1
SCHEMBL5011265 0.79 TRPV1 (0.45) TRPV1ATMSCN10ACYP2C9ALDH1A1
SCHEMBL5122154 0.78 TRPV1 (0.44) TRPV1ATMSCN10ASMN1; SMN2CYP2C9
SCHEMBL5122157 0.78 TRPV1 (0.44) TRPV1ATMSCN10ASMN1; SMN2CYP2C9
SCHEMBL5012286 0.72 TRPV1 (0.44) TRPV1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL5129267 0.72 TRPV1 (0.44) TRPV1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL3103219 0.70 TRPV1 (0.59) TRPV1SCN10AMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 EP claimed
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI TRPV1 57/4885ATM 4036/4885FAAH 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.